Inogen (INGN) Competitors $8.69 +0.10 (+1.16%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$8.69 0.00 (0.00%) As of 10/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INGN vs. BBNX, EMBC, TNDM, AXGN, CLPT, SIBN, BVS, AVNS, ZIMV, and BFLYShould you be buying Inogen stock or one of its competitors? The main competitors of Inogen include Beta Bionics (BBNX), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), ClearPoint Neuro (CLPT), SiBone (SIBN), Bioventus (BVS), AVANOS MEDICAL (AVNS), ZimVie (ZIMV), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry. Inogen vs. Its Competitors Beta Bionics Embecta Tandem Diabetes Care AxoGen ClearPoint Neuro SiBone Bioventus AVANOS MEDICAL ZimVie Butterfly Network Beta Bionics (NASDAQ:BBNX) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk. Do analysts prefer BBNX or INGN? Beta Bionics currently has a consensus target price of $24.44, indicating a potential upside of 10.46%. Inogen has a consensus target price of $11.00, indicating a potential upside of 26.58%. Given Inogen's higher possible upside, analysts plainly believe Inogen is more favorable than Beta Bionics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beta Bionics 1 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.69Inogen 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals believe in BBNX or INGN? 89.9% of Inogen shares are owned by institutional investors. 1.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is BBNX or INGN more profitable? Beta Bionics has a net margin of 0.00% compared to Inogen's net margin of -7.58%. Beta Bionics' return on equity of 0.00% beat Inogen's return on equity.Company Net Margins Return on Equity Return on Assets Beta BionicsN/A N/A N/A Inogen -7.58%-13.77%-8.52% Which has stronger earnings & valuation, BBNX or INGN? Inogen has higher revenue and earnings than Beta Bionics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeta Bionics$65.12M14.77-$54.76MN/AN/AInogen$343.47M0.68-$35.89M-$1.06-8.20 Does the media refer more to BBNX or INGN? In the previous week, Beta Bionics had 10 more articles in the media than Inogen. MarketBeat recorded 11 mentions for Beta Bionics and 1 mentions for Inogen. Beta Bionics' average media sentiment score of 0.65 beat Inogen's score of 0.00 indicating that Beta Bionics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBeta Bionics beats Inogen on 9 of the 14 factors compared between the two stocks. Get Inogen News Delivered to You Automatically Sign up to receive the latest news and ratings for INGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INGN vs. The Competition Export to ExcelMetricInogenMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$232.27M$6.99B$6.09B$10.54BDividend YieldN/A1.16%5.69%4.71%P/E Ratio-8.2027.6685.5627.61Price / Sales0.68195.34535.65201.06Price / CashN/A21.7337.9261.55Price / Book1.195.4513.036.76Net Income-$35.89M$178.04M$3.30B$275.88M7 Day Performance1.88%4.21%4.35%2.81%1 Month Performance1.88%12.27%9.50%9.24%1 Year Performance-3.44%34.25%85.16%35.42% Inogen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INGNInogen3.7505 of 5 stars$8.69+1.2%$11.00+26.6%-5.4%$232.27M$343.47M-8.201,030BBNXBeta Bionics1.9425 of 5 stars$19.85+1.6%$23.33+17.5%N/A$848.97M$65.12M0.00294Analyst ForecastInsider TradeEMBCEmbecta4.7967 of 5 stars$14.00+0.7%$19.00+35.7%+1.2%$812.94M$1.12B4.762,100Positive NewsAnalyst DowngradeTNDMTandem Diabetes Care4.172 of 5 stars$11.79-1.8%$22.44+90.3%-61.5%$810.83M$940.20M-3.822,650Analyst ForecastAXGNAxoGen3.1207 of 5 stars$17.26+0.6%$26.00+50.6%+26.1%$789.58M$187.34M-172.58450Analyst ForecastInsider TradeCLPTClearPoint Neuro0.7009 of 5 stars$21.57+0.1%$19.67-8.8%+154.7%$612.61M$31.39M0.00110News CoverageAnalyst ForecastGap UpSIBNSiBone3.967 of 5 stars$14.17+0.9%$23.67+67.0%+13.1%$606.13M$167.18M-25.30350Analyst ForecastBVSBioventus1.2251 of 5 stars$6.62-0.6%N/AN/A$550.64M$573.28M13.321,200News CoverageAnalyst ForecastAVNSAVANOS MEDICAL2.0854 of 5 stars$11.55-1.9%N/A-49.0%$546.16M$687.80M9.652,227Positive NewsZIMVZimVie1.3647 of 5 stars$18.90-0.1%$17.75-6.1%+21.8%$533.47M$443.40M-27.001,770Analyst ForecastBFLYButterfly Network2.2601 of 5 stars$1.96-2.7%$3.00+53.5%+48.2%$506M$82.06M0.00460Analyst ForecastOptions Volume Related Companies and Tools Related Companies Beta Bionics Alternatives Embecta Alternatives Tandem Diabetes Care Alternatives AxoGen Alternatives ClearPoint Neuro Alternatives SiBone Alternatives Bioventus Alternatives AVANOS MEDICAL Alternatives ZimVie Alternatives Butterfly Network Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INGN) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inogen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Inogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
